Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Anteris Technologies Expands PARADIGM Trial as US Recruitment Begins
Anteris Technologies expands PARADIGM trial as US recruitment kicks off; Medicare reimbursement secured, accelerating path to DurAVR THV commercialisation.
Latest Stories — SECTOR DESK
Alterity Therapeutics Granted ATH434 Patent to Treat Neurodegenerative Diseases
Alterity Therapeutics wins US patent for ATH434, extending protection to 2045 and backing Phase 3 push in MSA/Parkinsons, lifting ATH upside.
LTR Pharma Reports 93% SPONTAN Response in Real-World ED Cohort
LTR Pharma reports 93% real-world ED response to SPONTAN in treatment-experienced men, largest cohort to date, fueling ROXUS US plans.
Austco Healthcare Extends Direct Sales Presence with Acquisition of Nurse Call Platform Reseller
Austco to acquire MCS, bringing nurse-call in-house; boosts direct sales, adds $1.88m revenue and $0.82m EBITDA, earnings-accretive.
AVITA Medical Lifts Guidance as Record Quarter Brings Cash Flow Breakeven into View
AVITA Medical lifts 2026 revenue guidance after record Q2 US$21.7m; eyes cash-flow breakeven in Q4 as RECELL-led growth broadens international reach.
Clarity Pharmaceuticals Adds Two Complete Responses to SECuRE Trial Data
Clarity Pharma reports two new complete responses at 8GBq in SECuRE trial, boosting radiographic disease control to seven; PSA declines strong.
BlinkLab Reports Positive ADHD Assessment Results from European Dx2 Diagnostic Platform Study
BlinkLab reports ADHD Dx2 results: 82% sensitivity, 83% specificity in European study, signaling new smartphone-based diagnostic tool.
Entropy Neurodynamics Gains Ethics Approval for Eight-Indication TRP-8803 Trial
Entropy Neurodynamics gains ethics approval for Phase 1b/2a eight-indication TRP-8803 basket trial; first dosing this quarter.
Amplia Therapeutics Partners with Eli Lilly in FAK-KRAS Combination Lung Cancer Trial
Amplia Therapeutics partners with Eli Lilly for a Phase 1b/2b NSCLC trial of narmafotinib plus olomorasib, targeting KRAS G12C resistance and expanding market.
Paradigm Biopharmaceuticals Completes Phase 3 Enrolment Ahead of September Interim Analysis
Paradigm Biopharmaceuticals completes Phase 3 PARA_OA_012 enrolment for Zilosul in knee OA; interim analysis in Aug 2026; top-line results Q1 2027.
Adherium Reports Fourth Straight Quarter of Record RPM Revenue
Adherium logs fourth straight quarter of record RPM revenue, $479k to June, with 3,831 activated patients and a 68,000-patient pipeline as growth accelerates.
Imricor Launches US Operations with Cardiac Imaging System at Rady Children’s Hospital in San Diego
Imricor launches US ops with NorthStar MRI-guided cardiac mapping at Rady Children's after FDA paediatric clearance, enabling radiation-free procedures.